Edinburgh University Trading and Investment Club

Size: px
Start display at page:

Download "Edinburgh University Trading and Investment Club"

Transcription

1 Edinburgh University Trading and Investment Club Healthcare: Healthcare plc Asset Name Ticket Symbol Market Analysts Sector-Heads Sub-Industry healthcare plc :LSE London stock exchange George Coulter, Hassan Ashraf, Victor Hoet Ben Saddler, Juan Matias Healthcare Company Overview is a pre-wholesaling and contract logistics company, specialising in Pharmaceuticals, Healthcare, Veterinary and Consumer Products with the target of becoming the UK s biggest healthcare supply chain service. Recommendation Buy Target Stop Loss Allocation 160 shares Drivers 1. Healthcare product manufacturers are increasingly compelled to improve their efficiency. To do this they must reduce fixed costs and consequently opt for outsourcing options, such as the ones offers. 2. The constant growth and continuity of s commitment to its target of becoming the UK s biggest healthcare supply chain service. With a strong field of management and board, and promising financials, has the potential to proceed with this target. Contents Company Profile... 2 Industry Analysis... 3 Financial Analysis... 4 Currency... 5 Valuation... 6 DCF valuation and sensitivity analysis... 6 Investment Risks... 7 Investment Decision... 7 Key Figures Price P/E Div Yield 2.43% Mkt cap EPS 1.14 bil GDP Margin 5.19% D/E 8.02 ROE 23.16% ROA 11.93% Beta Empl d 8300 DCF VALUATION ( m) Present value of FCFs Terminal value 1, Terminal growth rate 1.25% PV of terminal value 1, Total 1, value Net debt/(cash) (2014e) Equity value 1, Total number of shares (m) Value per share( ) 3.85 upside/downside 18% source: Edison Investment Research, Bloomberg

2 Research Report Healthcare and Galliard will help them gain scientific expertise which will benefit other sections of the company. has considerable long-term funds and financing capabilities which will help them achieve their growth objectives. They expect to achieve a growth operating profit h in This will be due to the strong growth trend in Ashfield and Sharp. We remain very positive about our future growth prospects. Company Profile Operations 1. Ashfield Commercial & Medical Services Ashfield Commercial & Medical Services outsources multi-channel communications to healthcare professionals and patients. Ashfield is a global leader in this and operates in continental Europe, the UK, North America, Japan and South America. Ashfield Commercial & Medical Services offers outsourcing services in: Sales and marketing services Healthcare communications Event management Medical affairs and regulatory services 2. Supply chain services One supply chain service offered by Healthcare plc is called United Drug Supply Chain Services. This provides logistical and distribution services for pharmaceutical, biotech and consumer companies. This part of the company operates in the Republic of Ireland and Northern Ireland. Another supply chain is Aquilant Specialist Healthcare Services. This business is a distributor of specialist medical and scientific products. It also provides outsourced sales, marketing, distribution and engineering services to its clients. Aquilant Specialist operates in the Republic of Ireland, the UK and the Netherlands. 3. s packaging service Sharp Packaging Services provides clinical and commercial packaging, storage, logistics and project management services to the pharmaceutical and biotech industry. It has plants both in North America and Europe. have been successful in their previous targets. This can be seen by how much they have grown and the fact that they have made consistent acquisitions that have allowed them to gain a more global influence. Although the market in Ireland is still undergoing a difficult stage, 70% of their profit comes from Ashfield and Sharp. Both of these have been growing strongly and are expected to continue to succeed. This will allow them to achieve their goals. Management and Shareholders The company has a very respectable and trustworthy management team. The COO has been with the company since During this time has grown massively to become a major international player in healthcare outsourcing. Additionally, the CFO has been with the company for a significant number of years and most of the management has extensive experience in healthcare companies outside of, as many of them have served as executives in other pharmaceutical companies. Shareholders Shareholders of are primarily investment firms and asset management companies. M&G Investments are the largest stake holders with 24.1m shares amounting to 9.87% of the total equity. Other similar groups own 37.6% of the business. As there is no clear dominant shareholder, the company is effectively controlled by the managers and the chairman. Global Presence Healthcare, which employees 8,300 people across 20 countries, has a very global presence with operations in Europe, Asia, North and South America. Source: annual report 2014 Corporate Strategy aims to continue as they believe it will enable each division to sell services more successfully in what they believe is a rapidly changing market. They hope to facilitate more effective cross-selling, both within and across business units. The acquisition of KP360 2

3 Metrics Healthcare plc Mrkt Cap Industry Analysis Research Report Healthcare General Multiples Efficiency & margins Growth Liquidity Beta EPS D/E Div yield PEG P/E P/B ROE Gross Margin Net Margin Revenue Growth (5 yrs) EPS Growth (5 yrs) Quick Ratio Interest Cover 1.14B % Or 23.16% 17.16% 5.19% 23.8% 26.11% Celesio AG 4.06B % P/S 3.17% 10.84% 0.38% -0.9% ompetitor / / / / / / / / / / / / / / / Industry Competitiveness On the whole, most countries operates in are moving towards a more competitive stance in terms of their healthcare providers. The Pharmaceutical industry in particular is expanding as more players enter the market. Outsourcing for pharmaceuticals has consequently attracted many new entrants. Despite the competition, continues to grow and is becoming one of the most important actors in the market. Celesio AG, a provider of services for the pharmaceutical sector, is s primary competitor. Even if Celesio AG occupies a bigger part in the market with a market cap of 4.06B, it has recently shown instability and declining growth on the stock market, and does not compete with closely in terms of its financial data. In the short run, Celesio AG does not seem to pose a major threat to Healthcare. Future of the Industry The market for outsourcing in the commercial healthcare sector grows by 6-8% per year (Edison research, Bloomberg). The healthcare industry (along with the pharmaceutical industry) is forecast to continue growing substantially in the next few decades. The main reasons for this are, on one hand increasing lifespans (therefor increasing the need for healthcare), and also the continuous development of medical technology. With the growth of the healthcare sector, outsourcing and the demand for commercial solutions in pharmacies and hospitals have also grown. Healthcare has benefited from these growing outsourcing trends, and is well placed as demand for its services continue to grow along with the industry. Sources: Edison report (), Bloomberg Ft.markets.com Fundamentals of the Industry The growing demand for outsourcing and commercial solutions from pharmaceuticals is the industry s main driver. The main cause for this are healthcare companies seeking to improve efficiency and to lower their fixed costs; the outsourcing offers allows these companies to do so. The establishment of Supply chains are also fundamental in how companies operate in the industry, ensuring companies may achieve economies of scale. Strength - Growing outsourcing trends - Supply chains for growth Opportunities With growing demand for and other companies services in outsourcing, the outsourcing business has the opportunity to expand, especially with the help of globalisation as companies scatter around the world and tend to rely increasingly on outsourcing ( pharmaceuticals in this case). Weakness - Dependability on partnership with other pharmeucticals and healthcare companies Threats A change in the behaviour of healthcare and pharmaceuticals could be considered a threat to the outsourcing business in healthcare. This could be due to government regulation, healthcare reform or lack of investment in healthcare. 3

4 Research Report Healthcare OPERATING MARGIN Financial Analysis As demonstrated on the operating margin graph, healthcare has continued to outperform Celesio in the last four years. In 2014, has demonstrated an operating margin of 6.63%, whilst Celesio has had one of 0.71% (declining slightly from previous years). is well positioned to continue outperforming Celesio in the future. With a current ratio of 1.70 in 2014, is in a relatively good position to pay off its short term liabilities (in terms of its assets). Over four years, Celesio has consistently shown lower current ratios, indicating once again s advantage over its main competitor. The data for gearing between both companies shows us investment has been (over four years) overall less risky for. High gearing percentages for Celesio indicate the company s high level of loans (compared to shareholder funds). Higher loans indicate higher interest rates, and if these were to rise, investment in Celsio could be considered more risky, especially compared to is more consistent gearing levels. Return on capital employed (ROCE) measures profitability based on the amount of capital used. Unlike return on equity (ROE), ROCE is crucial in considering a company s debts and liabilities. Investment is more favourable with a higher ROCE percentage. shows higher percentages of ROCE over the last four years, demonstrating a consistently higher performance than Celesio AG. CURRENT RATIO Sources: - TheShareCentre.com () - FT.markets.co.uk - Celsio annual reports (2013,2012,2011) - annual report (2014) Celesio company CELESIO % 6.00% 5.00% 4.00% 3.00% 2.00% 1.00% 0.00% 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% 35.00% 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% CELESIO company % 3.69% 2.35% 6.63% CELESIO 1.39% 1.66% 1.90% 0.71% NET GEARING CELESIO company % 50.22% 51.80% 44.13% CELESIO 66% 71% 62% 21% RETURN ON CAPITAL EMPLOYED CELESIO company % 18.47% 10.51% 29.33% CELESIO 4.92% 9.40% 10.60% No data

5 Research Report Healthcare Currency Like a growing substantial number of healthcare companies, is based in Ireland, with the UK GDP Growth speculation that this is for tax purposes. However, the 3.00% majority of the operations take place in the United Kingdom. 2.00% Inflation The annual rate of inflation change for 2014 is 0.3%, a difference of 0.9% when compared to the statistics in years earlier of 1.2%. The small inflation change has a positive result for investors ensuring the security in the investment. Interest Rates The harmonized long term interest rates for Ireland is 1.22% (Jan 15) which is at low in recent times. More people are borrowing money due to the low interest rates meaning there is more money available for the public to borrow and use as investment. However, the UK s interest rate is currently at 0.5%. These low interest rates incentivize more people to consume goods rather than save as they will get a lower rate of return by keeping their money in the bank. 1.00% 0.00% 01/07/ /02/ /09/ /04/ % -2.00% -3.00% Economic Performance The UK economy grew by 2.6% in 2014, which was the country s fastest pace of growth since The growing economy is positive for investment in, investing in a growing market has the potential to capitalize on profit. Sources : IRELAND/Eurostat BANK of England BBC/economy 5

6 Valuation Research Report Healthcare Using the Discounted cash flow model, the forecast for s revenue growth rate suggests will continue to outperform the market in the next five years. Our assumptions rely on the previous 5 years of financial data has shown and the expanding market. Our main assumption is that the expansion of the market for outsourcing in healthcare will continue to push towards double digit growth. With a revenue growth of 23.8% over the last five years, is expected to continue growing at a similar rate. Nevertheless the probabilities are that s growth rate will slow down gradually. Variables must be taken into account such as unexpected increase in performance of competitors or reversely a decrease in competition (meaning an upside risk to predicitons) is also at risk in terms of poor integration or litigation which might alter predictions made (although unlikely). Decreasing outsourcing trends due to healthcare reform might very well be a downside risk to predictions. Although generally, our predictions are that outsourcing trends in the healthcare business will continue to secure position in the market. Source: Edison investment research, Bloomberg DCF valuation and sensitivity analysis VALUATION ( m) present value of FCFs Terminal value 1, Terminal growth rate 1.25% PV of terminal value 1, Total value 1, Net debt/(cash) (2014e) Equity value 1, Total number of shares(m) value per share( ) 3.85 upside/downside 18% source: Edison Investment Research, Bloomberg SENSITIVITY OF VALUE PER SHARE ( ) Terminal Growth rate WACC 0.25% 0.75% 1.25% 1.75% 2.25% 6.70% % % % %

7 Research Report Healthcare The main source of growth for is acquiring companies. As a result a failure to execute and properly integrate significant acquisitions will have a very negative effect on the company. Investment Risks Financial risk management Management of the financial risks facing the Group is governed by policies reviewed and approved by the Board. These policies primarily cover liquidity risk, interest rate risk, currency risk and credit risk. uses financial instruments throughout its businesses; borrowings and cash resources are used to finance the Group s operations; trade receivables and payables arise directly from operations; and swaps are used to manage the interest rate and currency risks and to achieve the desired currency profile of borrowings. Liquidity Risk Management has sufficient financing facilities available through cash flow generated from operating activities, loan notes issued, committed banking facilities and access to equity markets. This allows them to meet their short and long term funding requirements. Therefore the liquidity risk management is sufficient. Interest rate risk management is financed by a mixture of retained profits, bank borrowings and funding raised on the US private placement market. The Group s policy is to borrow in the required currencies at both fixed and floating rates of interest and use interest rate swaps to manage the Group s exposure to interest rate fluctuations. Again the company is in a good position with regards to interest rate management. Currency risk management Healthcare reporting currency and that in which its share capital is denominated is Euro. Given the nature of the Group s businesses, exposure arises in the normal course of business to other currencies, principally sterling and the US dollar. Dividend to acquire additional shares in the Company, is available in respect of the final dividend. The final date for receipt or cancellation of elections under the DRIP will be 27 January Credit risk management healthcare carries significant trade receivables and their recoverability is a material business risk. They uses a range of customer credit and collection procedures to actively manage its credit risk. s success is dependent on the management team performing to a high level. If fails to hold on to the current group of employees and if they fail to attract suitable people as the company grows, the company will suffer. has certain legal, obligatory obligations with regards to: Protecting patient information; health and safety for employees and within its centers Follows rules of procedure for selling and promoting products Failing to follow these correctly could result in loss of license, loss of reputation and risk of significant liability. Investment Decision Price Catalyst There is strong confidence in within the market: The consensus forecast amongst 6 polled investment analysts covering plc advised that the company will outperform the market (markets.ft.com) Price target Target for this stock purchase sits at 10% above the current price. If this achieved within a short time (3 months) we will look to revise this upwards. Exit Strategy If there is a decline in the stock price that goes below to stop loss set at 15% below the current price as of 16/03/2015. We see this stop loss only be hit in the event of negative consensus on the back of failure to secure companies in in acquisition deals. Source: annual report 2014 (PDF) markets.ft.com/research/markets/tearsheets/summar y?s=:lse 7

8 Research Report Healthcare Disclaimer The information and opinions in EUTIC Research were prepared or are disseminated by EUTIC. For valuation methodology and risks associated with any price targets referenced in this research report, please contact the EUTIC Fund Team at Important Disclosures EUTIC is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. EUTIC Research does not provide individually tailored investment advice. EUTIC Research has been prepared without regard to the circumstances and objectives of those who receive it. EUTIC recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in EUTIC Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. EUTIC Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. With the exception of information regarding EUTIC, EUTIC Research is based on public information. EUTIC makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in EUTIC Research change. Facts and views presented in EUTIC Research have not been reviewed by, and may not reflect information known to, professionals in other EUTIC business areas. EUTIC may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. EUTIC Research may not be distributed to the public media or quoted or used by the public media without the express written consent of EUTIC. EUTIC is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. EUTIC Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. The trademarks and service marks contained in EUTIC Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. EUTIC Research or portions of it may not be reprinted, sold or redistributed without the written consent of EUTIC. As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. 8

MATELAN Research. Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES

MATELAN Research. Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES MATELAN Research Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES 2/5/12 2/7/12 2/9/12 2/11/12 2/1/13 2/3/13 2/5/13 2/7/13 2/9/13

More information

UDG Healthcare plc An International Healthcare Services Organisation

UDG Healthcare plc An International Healthcare Services Organisation UDG Healthcare plc An International Healthcare Services Organisation Jefferies 2014 Global Healthcare Conference 2014 Liam FitzGerald, CEO 20 November 2014 1 FORWARD LOOKING STATEMENTS Some statements

More information

Financial Performance

Financial Performance Fundamental Value: $5.27 Market Price: $11.71 1 52 Week Range: $3.40 to $11.78 Recommendation: SELL 2 Symbol: JMMB Shares Outstanding: 1,463,386,752 units Market Value of Shares Outstanding: $17,136,258,865.92

More information

OptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures

OptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures Nov 14, 2014 Healthcare OptimizeRx Platform Potential Continues to Grow Other OTC OPRX Buy Rating Unchanged Current Price $0.87 Target Price $4.00 Market Capitalization 20.32M Shares Outstanding 23.36M

More information

INVESTMENT INSIGHTS. All-access, Flexible Approach to Emerging Markets

INVESTMENT INSIGHTS. All-access, Flexible Approach to Emerging Markets INVESTMENT INSIGHTS All-access, Flexible Approach to Emerging Markets Second Quarter 2015 1 1 Please note that the information herein represents the opinion of the portfolio manager and these opinions

More information

Successful value investing: the long term approach

Successful value investing: the long term approach Successful value investing: the long term approach Neil Walton, Head of Global Strategic Solutions, Schroders Do you have the patience to be a value investor? The long-term outperformance of a value investment

More information

Actuarial Society of India

Actuarial Society of India Actuarial Society of India EXAMINATIONS November 2004 SUBJECT - 108: Finance and Financial Reporting Indicative Solution S-108 Page 1 of 7 1 D 2 C 3 B 4 D 5 D 6 A 7 B 8 C 9 B 10 D 11 Trade credit is short-term

More information

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value UK Daily Letter 1 K3 Business Technology Group KBT : AIM : 144p BUY Target: 215p Bob Liao, CFA 44.20.7050.6654 bliao@canaccordgenuity.com COMPANY STATISTICS: 52-week Range: 0.82-1.50 Avg. Daily Vol. (000s):

More information

DATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015

DATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015 BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price

More information

Kingdee (268 HK) Buy (maintained) Target price: HK$3.58. Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$3.

Kingdee (268 HK) Buy (maintained) Target price: HK$3.58. Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$3. Equity Research Information Technology Aug 2, 21 Kingdee (28 HK) Buy (maintained) Target price: HK$.8 Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$.8 Lower-than-expected

More information

Mouwasat Medical Services Company - Mouwasat

Mouwasat Medical Services Company - Mouwasat Recommendation Overweight Fair Value (SR) 92.00 Price as of 2 nd of March 2014 (SR) 81.75 Expected return 12.5% Company data Tadawul symbol 4002.SE 52- week high (SR) 94.00 52-week low(sr) 52.25 YTD change

More information

Structured products. Precision tools. A guide for private investors.

Structured products. Precision tools. A guide for private investors. Structured products Precision tools. A guide for private investors. Structured products are listed securities available for trading on London Stock Exchange s regulated Main Market. Structured products

More information

Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3

Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3 Siddharth Rajeev, B.Tech, MBA, CFA Analyst November 5, 2015 Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3 Sector/Industry: E-commerce Market Data (as of November 5, 2015) Current Price $1.15 Fair

More information

Chapter 17: Financial Statement Analysis

Chapter 17: Financial Statement Analysis FIN 301 Class Notes Chapter 17: Financial Statement Analysis INTRODUCTION Financial ratio: is a relationship between different accounting items that tells something about the firm s activities. Purpose

More information

Empresaria (EMR.L) Empressive finish to the year

Empresaria (EMR.L) Empressive finish to the year 26 th January 2015 56 54 52 50 48 46 EMR EMPRESARIA ORD 5P Empresaria (EMR.L) Empressive finish to the year 44 42 40 38 Q1-2014 Q2-2014 Q3-2014 Q4-2014 Price: 43.0p Sourc e: Fides s a 12m High 56.0p 12

More information

Understanding Financial Management: A Practical Guide Guideline Answers to the Concept Check Questions

Understanding Financial Management: A Practical Guide Guideline Answers to the Concept Check Questions Understanding Financial Management: A Practical Guide Guideline Answers to the Concept Check Questions Chapter 3 Interpreting Financial Ratios Concept Check 3.1 1. What are the different motivations that

More information

price target of 7.40. We reiterate our Buy rating. Figure 1: Reported figures versus forecasts Source: First Berlin Equity Research, SFC Energy AG

price target of 7.40. We reiterate our Buy rating. Figure 1: Reported figures versus forecasts Source: First Berlin Equity Research, SFC Energy AG FIRST ERLIN Equity Research RATING Germany / Energy Primary exchange: Frankfurt Q3 figures PRICE TARGET 7.40 loomberg: F3C GR Return Potential 38.1% ISIN: DE0007568578 Risk Rating High PROJECT DELAYS URDEN

More information

Fundamental analysis. Course 10

Fundamental analysis. Course 10 Course 10 Fundamental analysis Topic 1: Fundamental analysis - an introduction... 3 Analysing individual companies... 3 What are you trying to learn about a company?... 4 Topic 2: Annual Report... 6 Sourcing

More information

BDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates

BDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates 8/11/1 8/1/11 8/3/11 8/5/11 8/7/11 8/9/11 8/11/11 8/1/12 8/3/12 8/5/12 8/7/12 8/9/12 MATELAN Research Preview Note Price as of 9/11/12: 8.69 12 November 212 Company / Sector Fair Value Recommendation BDI

More information

Company Fundamentals. THE CMC Markets Trading Smart Series

Company Fundamentals. THE CMC Markets Trading Smart Series Company Fundamentals THE CMC Markets Trading Smart Series How to evaluate company growth potential At any given point in time, share prices tend to represent the sum of expectations about its value from

More information

The Credit Crisis: A Monetary Explanation

The Credit Crisis: A Monetary Explanation M O R G A N S T A N L E Y R E S E A R C H Global Economics The Credit Crisis: A Monetary Explanation Joachim Fels Chief Global Fixed Income Economist & Co-Head of Global Economics 33 rd Annual IOSCO Conference

More information

Year-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14

Year-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14 This research is intended for UK institutional investors only and market professionals. It is not intended for retail customers and any retail customer should seek professional, independent advice before

More information

INVESTMENT CASE FULLY INTACT

INVESTMENT CASE FULLY INTACT Leifheit AG Q2 results due out on 12/08/2015 07/08/2015 INVESTMENT CASE FULLY INTACT Buy 60.00 EUR Close (06/08/2015) 47.68 EUR Bloomberg: LEI WKN: 646450 Sector Share price performance Consumer 52 week

More information

Tetragon Financial Group Limited ( TFG )

Tetragon Financial Group Limited ( TFG ) Tetragon Financial Group Limited ( TFG ) 12 August 2014 THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY OF TFG. THIS INFORMATION

More information

Ratio Analysis CBDC, NB. Presented by ACSBE. February, 2008. Copyright 2007 ACSBE. All Rights Reserved.

Ratio Analysis CBDC, NB. Presented by ACSBE. February, 2008. Copyright 2007 ACSBE. All Rights Reserved. Ratio Analysis CBDC, NB February, 2008 Presented by ACSBE Financial Analysis What is Financial Analysis? What Can Financial Ratios Tell? 7 Categories of Financial Ratios Significance of Using Ratios Industry

More information

20 May 2015 OpenLimit Holding AG. FIRST BERLIN Equity Research

20 May 2015 OpenLimit Holding AG. FIRST BERLIN Equity Research FIRST ERLIN Equity Research RATING Switzerland / Software Primary exchange: Frankfurt Q1 figures PRICE TARGET 1.10 loomberg: O5H GR Return Potential 37.3% ISIN: CH0022237009 Risk Rating High STRONG SALES

More information

euromicron AG Corrections to financial statements Hold 14.00 EUR

euromicron AG Corrections to financial statements Hold 14.00 EUR euromicron AG Corrections to financial statements 24/03/2015 Hold 14.00 EUR Close (23/03/2015) Bloomberg: EUCA Sector Share price performance 14.15 EUR WKN: A1K030 Technology 52 week high 14.18 52 week

More information

How Smaller Stocks May Offer Larger Returns

How Smaller Stocks May Offer Larger Returns Strategic Advisory Solutions April 2015 How Smaller Stocks May Offer Larger Returns In an environment where the US continues to be the growth engine of the developed world, investors may find opportunity

More information

Equity Analysis and Capital Structure. A New Venture s Perspective

Equity Analysis and Capital Structure. A New Venture s Perspective Equity Analysis and Capital Structure A New Venture s Perspective 1 Venture s Capital Structure ASSETS Short- term Assets Cash A/R Inventories Long- term Assets Plant and Equipment Intellectual Property

More information

2 September 2015 YOC AG. FIRST BERLIN Equity Research

2 September 2015 YOC AG. FIRST BERLIN Equity Research FIRST ERLIN Equity Research RATING Germany / Advertising Primary exchange: Frankfurt, Xetra Q2/15 Results PRICE TARGET 2.80 loomberg: YOC GR Return Potential 29.6% ISIN: DE0005932735 Risk Rating High SALES

More information

Sberbank Group s IFRS Results for 6 Months 2013. August 2013

Sberbank Group s IFRS Results for 6 Months 2013. August 2013 Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB

More information

SBERBANK GROUP S IFRS RESULTS. March 2015

SBERBANK GROUP S IFRS RESULTS. March 2015 SBERBANK GROUP S IFRS RESULTS 2014 March 2015 SUMMARY OF PERFORMANCE FOR 2014 STATEMENT OF PROFIT OR LOSS Net profit reached RUB 290.3bn (or RUB 13.45 per ordinary share), compared to RUB 362.0bn (or RUB

More information

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013

Focus on fleet customers SAF-HOLLAND Annual Financial Statements 2013 Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales

More information

Chapter Seven STOCK SELECTION

Chapter Seven STOCK SELECTION Chapter Seven STOCK SELECTION 1. Introduction The purpose of Part Two is to examine the patterns of each of the main Dow Jones sectors and establish relationships between the relative strength line of

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

Performance Food Group Company Reports First-Quarter Fiscal 2016 Earnings

Performance Food Group Company Reports First-Quarter Fiscal 2016 Earnings NEWS RELEASE For Immediate Release November 4, 2015 Investors: Michael D. Neese VP, Investor Relations (804) 287-8126 michael.neese@pfgc.com Media: Joe Vagi Manager, Corporate Communications (804) 484-7737

More information

Schroders Investment Trust ISA

Schroders Investment Trust ISA April 2016 Key Features of the Schroders Investment Trust ISA The Financial Conduct Authority is the independent financial services regulator. It requires us, Schroders, to give you this important information

More information

Diploma in Financial Management Examination Module B Paper DB1 incorporating subject areas: Financial Strategy; Risk Management

Diploma in Financial Management Examination Module B Paper DB1 incorporating subject areas: Financial Strategy; Risk Management Answers Diploma in Financial Management Examination Module B Paper DB1 incorporating subject areas: Financial Strategy; Risk Management June 2005 Answers 1 D Items 2, 3 and 4 are correct. Item 1 relates

More information

Financial Ratios and Quality Indicators

Financial Ratios and Quality Indicators Financial Ratios and Quality Indicators From U.S. Small Business Administration Online Women's Business Center If you monitor the ratios on a regular basis you'll gain insight into how effectively you

More information

Exhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY)

Exhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY) Capital Goods Manufacturing ector August 29, 214 Company Report Rating: HOLD TP: HK$ 4.8 H-hare price (HK$) 5.17 Est. share price return (7.16%) Est. dividend yield 1.39% Est. total return (5.77%) First

More information

Institute of Chartered Accountant Ghana (ICAG) Paper 2.4 Financial Management

Institute of Chartered Accountant Ghana (ICAG) Paper 2.4 Financial Management Institute of Chartered Accountant Ghana (ICAG) Paper 2.4 Financial Management Final Mock Exam 1 Marking scheme and suggested solutions DO NOT TURN THIS PAGE UNTIL YOU HAVE COMPLETED THE MOCK EXAM ii Financial

More information

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015 Company Presentation VTG AG Connecting worlds Analyst Conference April 14, 2015 Table of content 1 Highlights 2014 2 Performance & Financials 2014 3 Update on Strategy 4 Outlook 2015 5 Appendix 1 Executive

More information

ABF PAN ASIA BOND INDEX FUND An ETF listed on the Stock Exchange of Hong Kong

ABF PAN ASIA BOND INDEX FUND An ETF listed on the Stock Exchange of Hong Kong Important Risk Disclosure for PAIF: ABF Pan Asia Bond Index Fund ( PAIF ) is an exchange traded bond fund which seeks to provide investment returns that corresponds closely to the total return of the Markit

More information

Global high yield: We believe it s still offering value December 2013

Global high yield: We believe it s still offering value December 2013 Global high yield: We believe it s still offering value December 2013 02 of 08 Global high yield: we believe it s still offering value Patrick Maldari, CFA Senior Portfolio Manager North American Fixed

More information

Khambatta Securities Ltd.

Khambatta Securities Ltd. Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue

More information

for Analysing Listed Private Equity Companies

for Analysing Listed Private Equity Companies 8 Steps for Analysing Listed Private Equity Companies Important Notice This document is for information only and does not constitute a recommendation or solicitation to subscribe or purchase any products.

More information

Portfolio Bonds. Balanced Growth

Portfolio Bonds. Balanced Growth Portfolio Bonds Balanced Growth SALE PERIOD: 1 June 4 September 2015 INVESTMENT PERIOD: About 6 years REFERENCE ASSETS: 3 equity indices which represent the US, European and Pan Asian markets Portfolio

More information

Emlak Konut REIT. Equity / Large Cap. / Real Estate Investment Trust. Bloomberg: EKGYO TI OUTPERFORM. Reuters: EKGYO IS.

Emlak Konut REIT. Equity / Large Cap. / Real Estate Investment Trust. Bloomberg: EKGYO TI OUTPERFORM. Reuters: EKGYO IS. Equity / Large Cap. / Real Estate Investment Trust Emlak Konut REIT Bloomberg: EKGYO TI Reuters: EKGYO IS 01/06/2012 Company Report OUTPERFORM Upside Potential* 42% Good entry point for the long term investors

More information

S&P 500 outlook: Close to peak for 2015

S&P 500 outlook: Close to peak for 2015 S&P 500 outlook: Close to peak for 2015 August 12, 2015 Markets and Products Analysis INVESTMENT PORTOFOLIO ANALYSIS DIVISION Important Disclaimer in page 2 1 Disclaimer Disclaimer: The information herein

More information

DCF and WACC calculation: Theory meets practice

DCF and WACC calculation: Theory meets practice www.pwc.com DCF and WACC calculation: Theory meets practice Table of contents Section 1. Fair value and company valuation page 3 Section 2. The DCF model: Basic assumptions and the expected cash flows

More information

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7%

GrandVision reports Revenue growth of 13.8% and EPS growth of 31.7% GrandVision reports Revenue of 13.8% and EPS of 31.7% Schiphol, the Netherlands 16 March 2015. GrandVision NV (EURONEXT: GVNV) publishes Full Year and Fourth Quarter 2015 results. 2015 Highlights Revenue

More information

Commodities. Precious metals as an asset class. April 2011. What qualifies as an asset class? What makes commodities an asset class?

Commodities. Precious metals as an asset class. April 2011. What qualifies as an asset class? What makes commodities an asset class? Commodities Precious metals as an asset class April 2011 What qualifies as an asset class? Broadly speaking, an asset class is simply a grouping of assets that possess similar characteristics. Defining

More information

Key issues in bank lending

Key issues in bank lending Key issues in bank lending Introduction Welcome to Keynotes. Keynotes is a monthly event and publication to help early stage businesses get to grips with key legal issues. A bit about us Keynotes is brought

More information

Municipal Bond Tax Exemption Investment Primer

Municipal Bond Tax Exemption Investment Primer WEALTH MANAGEMENT INVESTMENT RESOURCES APRIL 20, 2015 Municipal Bond Tax Exemption Investment Primer JOHN M DILLON Managing Director Morgan Stanley Wealth Management John.Dillon2@morganstanley.com MATTHEW

More information

INDUSTRY OVERVIEW SOURCE OF INFORMATION. Report prepared by Euromonitor

INDUSTRY OVERVIEW SOURCE OF INFORMATION. Report prepared by Euromonitor The information that appears in this Industry Overview has been prepared by Euromonitor International Limited and reflects estimates of market conditions based on publicly available sources and trade opinion

More information

ANZ ETFS S&P/ASX 300 HIGH YIELD PLUS ETF. (ASX Code: ZYAU)

ANZ ETFS S&P/ASX 300 HIGH YIELD PLUS ETF. (ASX Code: ZYAU) ANZ ETFS S&P/ASX 300 HIGH YIELD PLUS ETF (ASX Code: ZYAU) INVESTMENT BUILDING BLOCKS FOR A CHANGING WORLD Introducing a suite of innovative exchange traded funds (ETFs) designed for Australian investors

More information

SAINSBURY S VS. MORRISONS AN INVESTMENT DECISION BASED ON FINANCIAL ANALYSIS

SAINSBURY S VS. MORRISONS AN INVESTMENT DECISION BASED ON FINANCIAL ANALYSIS No. 3/2012 SAINSBURY S VS. MORRISONS AN INVESTMENT DECISION BASED ON FINANCIAL ANALYSIS Zuzana Kalmárová Roehampton University Business School Southlands College, 80 Roehampton Lane, London, SW155SL zuzana.kalmarova@gmail.com

More information

Invesco Funds Series 1-5 Consolidated Prospectus

Invesco Funds Series 1-5 Consolidated Prospectus Invesco Funds Series 1-5 Consolidated Prospectus 26 November 2010 Invesco Funds Series 1 Invesco Funds Series 2 Invesco Funds Series 3 Invesco Funds Series 4 Invesco Funds Series 5 Each an open-ended umbrella

More information

Deutsche Bank Global Transaction Banking. What DR investors are buying: An analysis of investment drivers for depositary receipts

Deutsche Bank Global Transaction Banking. What DR investors are buying: An analysis of investment drivers for depositary receipts What DR investors are buying: An analysis of investment drivers for depositary receipts What DR investors are buying: An analysis of investment drivers for depositary receipts Conventional methods of trying

More information

Preparing Your Fixed Income Portfolio for Rising Interest Rates

Preparing Your Fixed Income Portfolio for Rising Interest Rates fixed income portfolio august 2013 2 Bond Fundamentals 3 Products to Hedge Interest Rates 4 Strategies to Mitigate the Effect of Rising Rates 6 Investment Considerations Preparing Your Fixed Income Portfolio

More information

CONVERTIBLE DEBENTURES A PRIMER

CONVERTIBLE DEBENTURES A PRIMER What are convertible debentures? CONVERTIBLE DEBENTURES A PRIMER They are hybrid securities, combining the features of a conventional debenture with the option of converting, under certain circumstances,

More information

G5 Entertainment. G5 Entertainment. Quarter Update Q3 15. Amended strategy and boosted profitability

G5 Entertainment. G5 Entertainment. Quarter Update Q3 15. Amended strategy and boosted profitability Quarter Update Q3 15 Last updated on the 18/11/2015 Share Price Market Capitalisation Target Price 41.00 SEK 360.8m SEK 49.05 SEK Amended strategy and boosted profitability reported their third quarter

More information

Strategic Research: Contracts For Difference

Strategic Research: Contracts For Difference Strategic Research: Contracts For Difference Ian Littlewood Contracts For Difference April 2007 Strategic Research reports from Thomson Financial are designed to enable strategic decision-making for investor

More information

Tupras OUTPERFORM (M) 15 February 2010. Strong 2009 results on refining side...

Tupras OUTPERFORM (M) 15 February 2010. Strong 2009 results on refining side... Equity / Large Cap. / Petroleum and Energy 15 February 2010 Bloomberg: TUPRS TI Strong 2009 results on refining side... Reuters: TUPRS IS released its 2009 year end tax purpose financials. The main differences

More information

Econ 330 Exam 1 Name ID Section Number

Econ 330 Exam 1 Name ID Section Number Econ 330 Exam 1 Name ID Section Number MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question. 1) If during the past decade the average rate of monetary growth

More information

S&P 500 Low Volatility Index

S&P 500 Low Volatility Index S&P 500 Low Volatility Index Craig J. Lazzara, CFA S&P Indices December 2011 For Financial Professional/Not for Public Distribution There s nothing passive about how you invest. PROPRIETARY. Permission

More information

Prospectus Socially Responsible Funds

Prospectus Socially Responsible Funds Prospectus Socially Responsible Funds Calvert Social Investment Fund (CSIF) Balanced Portfolio Equity Portfolio Enhanced Equity Portfolio Bond Portfolio Money Market Portfolio Calvert Social Index Fund

More information

Financial Analysis Project. Apple Inc.

Financial Analysis Project. Apple Inc. MBA 606, Managerial Finance Spring 2008 Pfeiffer/Triangle Financial Analysis Project Apple Inc. Prepared by: Radoslav Petrov Course Instructor: Dr. Rosemary E. Minyard Submission Date: 5 May 2008 Petrov,

More information

Why ECB QE is Negative for Commodities. Investment Research & Advisory. Deltec International Group

Why ECB QE is Negative for Commodities. Investment Research & Advisory. Deltec International Group Atul Lele alele@deltecinv.com +1 242 302 4135 David Munoz dmunoz@deltecinv.com +1 242 302 4106 David Frazer dfrazer@deltecinv.com +1 242 302 4156 Why ECB QE is Negative for Commodities Recent ECB Quantitative

More information

CFS. Syllabus. Certified Finance Specialist. International benchmark in Finance profession

CFS. Syllabus. Certified Finance Specialist. International benchmark in Finance profession CFS Certified Finance Specialist Syllabus International benchmark in Finance profession Certified Finance Specialist Summary: This award will provide candidates the opportunity to gain advanced level knowledge

More information

2 11,455. Century Small Cap Select Instl SMALL-CAP as of 09/30/2015. Investment Objective. Fund Overview. Performance Overview

2 11,455. Century Small Cap Select Instl SMALL-CAP as of 09/30/2015. Investment Objective. Fund Overview. Performance Overview SMALL-CAP as of 09/30/2015 Investment Objective Century Small Cap Select Fund (CSCS) seeks long-term capital growth. Performance Overview Cumulative % Annualized % Quarter Year Since to Date to Date 1

More information

Sale of receivables from the Spanish Public Health Care Sector. Cleaning up your Balance Sheet

Sale of receivables from the Spanish Public Health Care Sector. Cleaning up your Balance Sheet Sale of receivables from the Spanish Public Health Care Sector Cleaning up your Balance Sheet Index i. Problem ii. Solution The Non Recourse sale of receivables to IOS Finance Key Accounting Considerations

More information

Cinda International. Hold (Initiation) Target price: HK$1.55. Facing intense competition from Chinese brokers in HK; initiate at Hold

Cinda International. Hold (Initiation) Target price: HK$1.55. Facing intense competition from Chinese brokers in HK; initiate at Hold Equity Research Financials Cinda (111 HK) Hold (Initiation) Target price: HK$1.55 Facing intense competition from Chinese brokers in HK; initiate at Hold China Cinda s international business platform Cinda

More information

Chapter 16: Financial Risk Management

Chapter 16: Financial Risk Management Chapter 16: Financial Risk Management Introduction Overview of Financial Risk Management in Treasury Interest Rate Risk Foreign Exchange (FX) Risk Commodity Price Risk Managing Financial Risk The Benefits

More information

Aksa Enerji Outperform (Maintained)

Aksa Enerji Outperform (Maintained) 01.14 03.14 05.14 07.14 09.14 11.14 01.15 03.15 05.15 May 26, 2015 Outperform (Maintained) Turkey - Equity - Company Update On the verge of a new era s commissioning of the Company s first lignite power

More information

VALUING BANKING STOCKS

VALUING BANKING STOCKS June 2003 VALUING BANKING STOCKS A Synopsis on the Basic Models The Pros & Cons Utilizing Evidence from European Equity Research Practices Nicholas I. Georgiadis Director of Research - VRS ( Valuation

More information

Rating Methodology by Sector. Non-life Insurance

Rating Methodology by Sector. Non-life Insurance Last updated: March 26, 2012 Rating Methodology by Sector Non-life Insurance *This rating methodology is a modification of the rating methodology made public on July 13, 2011, and modifications are made

More information

Fundamentals Level Skills Module, Paper F9

Fundamentals Level Skills Module, Paper F9 Answers Fundamentals Level Skills Module, Paper F9 Financial Management June 2008 Answers 1 (a) Calculation of weighted average cost of capital (WACC) Cost of equity Cost of equity using capital asset

More information

Aksa Enerji OUTPERFORM. 07 September 2011. Massive cut in 2011 production target more than priced in... Upside Potential* 80%

Aksa Enerji OUTPERFORM. 07 September 2011. Massive cut in 2011 production target more than priced in... Upside Potential* 80% Equity / Mid Cap. / Utilities 07 September 2011 Bloomberg: AKSEN TI Massive cut in 2011 production target more than priced in... We have revised our valuation for reflecting the changes in the company

More information

Cash flow before tax 1,587 1,915 1,442 2,027 Tax at 28% (444) (536) (404) (568)

Cash flow before tax 1,587 1,915 1,442 2,027 Tax at 28% (444) (536) (404) (568) Answers Fundamentals Level Skills Module, Paper F9 Financial Management June 2014 Answers 1 (a) Calculation of NPV Year 1 2 3 4 5 $000 $000 $000 $000 $000 Sales income 5,670 6,808 5,788 6,928 Variable

More information

Fundamentals Level Skills Module, Paper F9

Fundamentals Level Skills Module, Paper F9 Answers Fundamentals Level Skills Module, Paper F9 Financial Management December 2008 Answers 1 (a) Rights issue price = 2 5 x 0 8 = $2 00 per share Theoretical ex rights price = ((2 50 x 4) + (1 x 2 00)/5=$2

More information

BDI BioEnergy Internat. 14.5 Buy

BDI BioEnergy Internat. 14.5 Buy 20/08/13 20/10/13 20/12/13 20/02/14 20/04/14 20/06/14 20/08/14 20/10/14 20/12/14 20/02/15 20/04/15 20/06/15 MATELAN Research Update Note Price as of 20/08/15: 10.80 21 August 2015 Company / Sector Fair

More information

Registered country information Vanguard Investment Series plc and Vanguard Funds plc

Registered country information Vanguard Investment Series plc and Vanguard Funds plc Registered country information Vanguard Investment Series plc and Vanguard Funds plc The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.

More information

Fiduciary Management. What is Fiduciary Management?

Fiduciary Management. What is Fiduciary Management? Fiduciary Management What is Fiduciary Management? Fiduciary Management can be defined as a pension management solution which focuses on achieving the long term goals of a pension fund within a defined

More information

Longfor (960 HK) Unrated Real Estate Development Industry

Longfor (960 HK) Unrated Real Estate Development Industry 20 Septemper 2012 Equity Focus Key Data Share price (HK$) 11.78 52Wk H/L(HK$) 13.5/6.5 Issued shares (mn) 5,167.3 Market cap (HK$mn) 60,974 30-day avg vol (HK$mn) 137.14 Auditors Deloitte Major shareholder:

More information

Forecasting and Valuation of Enterprise Cash Flows 1. Dan Gode and James Ohlson

Forecasting and Valuation of Enterprise Cash Flows 1. Dan Gode and James Ohlson Forecasting and Valuation of Enterprise Cash Flows 1 1. Overview FORECASTING AND VALUATION OF ENTERPRISE CASH FLOWS Dan Gode and James Ohlson A decision to invest in a stock proceeds in two major steps

More information

Keyware Technologies N.V- valuation highlights

Keyware Technologies N.V- valuation highlights Keyware Technologies N.V- valuation highlights This memorandum brings a short summary of Keyware Technologies N.V's (hereinafter 'Keyware' or the 'Company') valuation report as of December 31, 2014. This

More information

investment research policy

investment research policy October 2014 investment research policy The purpose of this research policy is to ensure that retail investors understand the way in which we arrive at our view on an investment. This includes whether

More information

5 Year UK Growth Certificate

5 Year UK Growth Certificate 5 Year UK Growth Certificate The 5 Year UK Growth Certificate (the Certificate ) provides the opportunity to make a fixed return equal to 35.75% of the Issue Price (gross) on the Maturity Date. Whether

More information

Management s Discussion and Analysis

Management s Discussion and Analysis Management s Discussion and Analysis of Financial Conditions and Results of Operations For the quarter and six months ended June 30, 2012 All figures in US dollars This Interim Management s Discussion

More information

FINANCIAL INFORMATION CONSOLIDATED FINANCIAL STATEMENTS. Risk management

FINANCIAL INFORMATION CONSOLIDATED FINANCIAL STATEMENTS. Risk management 167 Risk management Group risk management Group Risk Management supports the Board of Directors, the Executive Committee and the management teams of the Group companies in their strategic decisions. Group

More information

Bright Smart (1428 HK)

Bright Smart (1428 HK) Equity Research Financials Bright Smart (1428 ) Hold (initiation) Target price: $1.70 Local broker with high ROE; initiate at Hold Local broker with expansion ambition Bright Smart is a securities, commodities

More information

The UK Retail Bond Market H1 2011 Performance Update

The UK Retail Bond Market H1 2011 Performance Update 1. Introduction The UK Retail Bond Market H1 2011 Performance Update Over the last 6 months, 7 transactions have been launched in the retail bond market in the UK, raising 540 million - with a further

More information

9 Questions Every ETF Investor Should Ask Before Investing

9 Questions Every ETF Investor Should Ask Before Investing 9 Questions Every ETF Investor Should Ask Before Investing 1. What is an ETF? 2. What kinds of ETFs are available? 3. How do ETFs differ from other investment products like mutual funds, closed-end funds,

More information

Al Razzi Holding Company

Al Razzi Holding Company 4 February 214 Analyst Analyst Title Recomm. Subsidiaries, 213 Stake (%) Shifa Healthcare 1% Warba Medical Supplies 8% Dawaa Manufacturing 99% Environmental Industries Held through Shifa Healthcare NR

More information

STANDARD LIFE INVESTMENTS PROPERTY INCOME TRUST LIMITED

STANDARD LIFE INVESTMENTS PROPERTY INCOME TRUST LIMITED This document is issued by Standard Life Investments Property Income Trust Limited (the "Company") and is made available by Standard Life Investments (Corporate Funds) Limited (the AIFM ) solely in order

More information

Using Accounts to Interpret Performance

Using Accounts to Interpret Performance Using s to Interpret Performance ing information is used by stakeholders to judge the performance and efficiency of a business Different stakeholders will look for different things: STAKEHOLDER Shareholders

More information

AIFMD investor information document Temple Bar Investment Trust PLC

AIFMD investor information document Temple Bar Investment Trust PLC AIFMD investor information document Temple Bar Investment Trust PLC Temple Bar Investment Trust PLC (the Company ) was incorporated in 1926 with the registered number 214601. The Company carries on business

More information